Medicine and Dentistry
Neoplasm
100%
Diseases
92%
Surgery
61%
Malignant Neoplasm
58%
Nodular Melanoma
43%
Breast Cancer
36%
Injury
34%
Symptom
31%
Clinical Trial
31%
Surgeon
30%
Overall Survival
30%
Psoriatic Arthritis
30%
Immunotherapy
29%
Quality of Life
28%
Recurrent Disease
27%
Infection
26%
Radiation Therapy
25%
Adverse Event
25%
Aneurysm
24%
Metastatic Carcinoma
22%
Biological Marker
21%
Lung Cancer
20%
Bleeding
20%
Adult Spine Deformity
20%
Placebo
19%
Apoplexy
19%
Oncology
19%
Ovarian Cancer
19%
Odds Ratio
18%
Embolization
18%
Cancer
18%
Diagnosis
17%
T Cell
17%
Glioblastoma
17%
COVID-19
16%
Systematic Review
16%
Health Care Cost
16%
Biopsy
15%
Arm
15%
Progression Free Survival
15%
Prevalence
15%
Drug Therapy
15%
Magnetic Resonance Imaging
14%
Retroperitoneal Lymph Node Dissection
14%
Multiple Sclerosis
14%
Chronic Kidney Disease
13%
Anatomy
13%
Pelvis
13%
Clinician
13%
Neck
12%
Partial Nephrectomy
12%
Psoriasis
12%
Cervical Cancer
12%
Hazard Ratio
12%
Computer Assisted Tomography
12%
Brain Metastasis
12%
Metastatic Melanoma
12%
Non Small Cell Lung Cancer
11%
Prostate Cancer
11%
Spine Surgery
11%
Randomized Controlled Trial
11%
Lymph Node
11%
Heart Failure
11%
Diabetes
11%
Gynecological Oncology
11%
Pediatrics
11%
Solid Malignant Neoplasm
10%
In Vitro
10%
Surgical Technique
10%
Symptomatic Treatment
10%
Patient-Reported Outcome
10%
Combination Therapy
9%
Health Care
9%
Body Mass Index
9%
Cardiovascular System
9%
Cancer Cell
9%
Kyphosis
9%
Bevacizumab
9%
Meta-Analysis
9%
Drug Megadose
8%
Tumor Cell
8%
Nonalcoholic Fatty Liver
8%
Logistic Regression Analysis
8%
Immune Response
8%
Spondylarthritis
8%
Ganglioglioma
8%
Cisplatin
8%
Krukenberg Tumor
8%
Brain Ischemia
7%
Phase II Trials
7%
Arteriovenous Malformation
7%
Atrial Fibrillation
7%
Alzheimer's Disease
7%
Sentinel Lymph Node
7%
Sentinel Node
7%
Rheumatology
7%
Operation Duration
7%
Survival Rate
7%
Multivariate Analysis
7%
Pembrolizumab
7%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
70%
Neoplasm
64%
Psoriatic Arthritis
55%
Malignant Neoplasm
48%
Placebo
37%
Clinical Trial
35%
Adverse Event
31%
Chemotherapy
29%
Overall Survival
24%
Melanoma
24%
Infection
21%
Biological Marker
19%
Progression Free Survival
18%
Breast Cancer
18%
Psoriasis
17%
Solid Malignant Neoplasm
17%
Glioblastoma
17%
Immunotherapy
16%
Lung Cancer
15%
Multiple Sclerosis
14%
Symptom
13%
Phase II Trials
12%
Recurrent Disease
12%
Ovary Cancer
12%
Non Small Cell Lung Cancer
11%
Monotherapy
11%
Prostate Cancer
11%
Cisplatin
10%
Mouse
10%
Rheumatoid Arthritis
10%
Bevacizumab
10%
Pharmacokinetics
10%
Cytokine
10%
Disease Activity
9%
Injury
9%
Prevalence
9%
Uterine Cervix Cancer
9%
Randomized Controlled Trial
9%
Pembrolizumab
8%
Interleukin 2
8%
Remission
8%
Inflammation
8%
Spondylarthritis
7%
Tolerability
7%
Methotrexate
7%
Chronic Kidney Failure
7%
Metastatic Melanoma
7%
Monoclonal Antibody
7%
Combination Therapy
7%
Receptor
7%
Paclitaxel
7%
Bleeding
7%
Disease Exacerbation
7%
Interferon
6%
Tumor Necrosis Factor
6%
Secukinumab
6%
Epidermal Growth Factor Receptor
6%
Tumor Growth
6%
Brain Metastasis
6%
Retinol
6%
Antitumor Activity
6%
Nonalcoholic Fatty Liver
6%
Comorbidity
6%
Ipilimumab
6%
Cohort Study
5%
Colorectal Cancer
5%
Chronic Lymphatic Leukemia
5%
Carboplatin
5%
Ovary Carcinoma
5%
Phase I Trials
5%
Alzheimer's Disease
5%
Ankylosing Spondylitis
5%
Arthritis
5%
Randomized Clinical Trial
5%
Adalimumab
5%
Cyclophosphamide
5%
Tumor Necrosis Factor Inhibitor
5%
Certolizumab Pegol
5%
Side Effect
5%
Renal Cell Carcinoma
5%
Aneurysm
5%